Phase II evaluation of bleomycin. A Southwest Oncology Group study

Charles D. Haas, Charles A. Coltman, Jeffrey A. Gottlieb, Arthur Haut, James K. Luce, Robert W. Talley, Bohumil Samal, Henry E. Wilson, Barth Hoogstraten

Research output: Contribution to journalArticlepeer-review

78 Scopus citations


Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice‐weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less, likely to cause pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were Associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.

Original languageEnglish (US)
Pages (from-to)8-12
Number of pages5
Issue number1
StatePublished - Jul 1976
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II evaluation of bleomycin. A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this